PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart. Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Prevalence of non-GC phenotype
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of mutations, copy number abnormalities, and structural variants
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic lesions
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by gene expression signatures
Timeframe: 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic methylation profile
Timeframe: 12 months: from the end of samples collection to the end of study analysis
International Extranodal Lymphoma Study Group - IELSG